why choose us

First received: September 25, 2023

Clinical Trial: Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions

Study Status: Completed

Recruit Status: RECRUITING

Condition: High Grade Glioma

Study Type: INTERVENTIONAL


Official Title: A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With

Brief Summary: This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma.BDTX-1535 was designed to block a growth signal important to some cancers.BDTX-1535 is being tested in this study to see if it can be given safely to people who have tumors that can be dependent on that growth signal because of changes in a protein called EGFR.These gene changes are called amplifications, mutations, fusions or alterations and are found only in the tumors.

Read more